tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

HK:6855 Stock Latest News

Ascentage Pharma presents data from Phase Ib/II study of Lisaftoclax
The FlyAscentage Pharma presents data from Phase Ib/II study of Lisaftoclax
13h ago
AAPG
Ascentage Pharma presents data for Lisaftoclax at 2025 ASH
PremiumThe Fly
Ascentage Pharma presents data for Lisaftoclax at 2025 ASH
21h ago
AAPG
Ascentage Pharma’s Olverembatinib Phase III Trial Cleared by US FDA and EMA
PremiumCompany Announcements
Ascentage Pharma’s Olverembatinib Phase III Trial Cleared by US FDA and EMA
4d ago
6855
Ascentage Pharma initiated with an Outperform at Oppenheimer
PremiumThe Fly
Ascentage Pharma initiated with an Outperform at Oppenheimer
4d ago
AAPG
Ascentage Pharma management to meet with Oppenheimer
PremiumThe Fly
Ascentage Pharma management to meet with Oppenheimer
6d ago
AAPG
Ascentage Pharma Grants Further RSU Awards to Strengthen Growth Strategy
PremiumCompany AnnouncementsAscentage Pharma Grants Further RSU Awards to Strengthen Growth Strategy
11d ago
6855
Ascentage Pharma initiated with a Buy at Truist
Premium
The Fly
Ascentage Pharma initiated with a Buy at Truist
14d ago
AAPG
Ascentage Pharma initiated with a Buy at BTIG
Premium
The Fly
Ascentage Pharma initiated with a Buy at BTIG
28d ago
AAPG
Pinterest downgraded, Tractor Supply upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Pinterest downgraded, Tractor Supply upgraded: Wall Street’s top analyst calls
1M ago
ADM
LMT
Ascentage Pharma initiated with an Overweight at Piper Sandler
PremiumThe Fly
Ascentage Pharma initiated with an Overweight at Piper Sandler
1M ago
AAPG
Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks
PremiumRatings
Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks
1M ago
AAPG
Ascentage Pharma to Showcase Latest Clinical Study Results at ASH 2025
PremiumCompany Announcements
Ascentage Pharma to Showcase Latest Clinical Study Results at ASH 2025
1M ago
6855
Ascentage Pharma’s Promising HR-MDS Study: A Potential Game Changer
PremiumCompany AnnouncementsAscentage Pharma’s Promising HR-MDS Study: A Potential Game Changer
1M ago
6855
Ascentage Pharma’s Promising Study on Lisaftoclax for AML: A Potential Game-Changer?
Premium
Company Announcements
Ascentage Pharma’s Promising Study on Lisaftoclax for AML: A Potential Game-Changer?
1M ago
6855
Ascentage Pharma’s GLORA Study: A Promising Development in CLL/SLL Treatment
Premium
Company Announcements
Ascentage Pharma’s GLORA Study: A Promising Development in CLL/SLL Treatment
1M ago
6855
Ascentage Pharma’s APG-5918: A Promising Anemia Treatment in Phase 1 Trials
PremiumCompany Announcements
Ascentage Pharma’s APG-5918: A Promising Anemia Treatment in Phase 1 Trials
1M ago
6855
Ascentage Pharma’s Innovative AML Treatment Study: A Market Game Changer?
PremiumCompany Announcements
Ascentage Pharma’s Innovative AML Treatment Study: A Market Game Changer?
1M ago
6855
Ascentage Pharma’s APG-2449: A Promising Phase I Study for Advanced Solid Tumors
PremiumCompany Announcements
Ascentage Pharma’s APG-2449: A Promising Phase I Study for Advanced Solid Tumors
1M ago
6855
Ascentage Pharma’s Phase 3 Study on Olverembatinib: A Potential Game-Changer for CML Treatment
PremiumCompany Announcements
Ascentage Pharma’s Phase 3 Study on Olverembatinib: A Potential Game-Changer for CML Treatment
1M ago
6855
Ascentage Pharma’s APG-2575 Study: A Potential Game-Changer for CLL/SLL Treatment?
PremiumCompany AnnouncementsAscentage Pharma’s APG-2575 Study: A Potential Game-Changer for CLL/SLL Treatment?
1M ago
6855
Ascentage Pharma’s Promising Study on Lisaftoclax for CLL/SLL: A Potential Game-Changer?
Premium
Company Announcements
Ascentage Pharma’s Promising Study on Lisaftoclax for CLL/SLL: A Potential Game-Changer?
1M ago
6855
Ascentage Pharma’s HQP1351 Study: A Promising Step in Cancer Treatment
Premium
Company Announcements
Ascentage Pharma’s HQP1351 Study: A Promising Step in Cancer Treatment
1M ago
6855

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >